January 4, 2011
CONTACT: Karen Kreeger
Male Pattern Balding May Be Due to Stem Cell Inactivation, According to Penn Study
PHILADELPHIA – Given the amount of angst over male pattern balding, surprisingly little is known about its cause at the cellular level. In a new study, published in the Journal of Clinical Investigation, a team led by George Cotsarelis, MD, chair of the Department of Dermatology at the University of Pennsylvania School of Medicine, has found that stem cells play an unexpected role in explaining what happens in bald scalp.
Using cell samples from men undergoing hair transplants, the team compared follicles from bald scalp and non-bald scalp, and found that bald areas had the same number of stem cells as normal scalp in the same person. However, they did find that another, more mature cell type called a progenitor cell was markedly depleted in the follicles of bald scalp.
The researchers surmised that balding may arise from a problem with stem-cell activation rather than the numbers of stem cells in follicles. In male pattern balding, hair follicles actually shrink; they don’t disappear. The hairs are essentially microscopic on the bald part of the scalp compared to other spots.
“We asked: ‘Are stem cells depleted in bald scalp?’” says Cotsarelis. “We were surprised to find the number of stem cells was the same in the bald part of the scalp compared with other places, but did find a difference in the abundance of a specific type of cell, thought to be a progenitor cell,” he says. “This implies that there is a problem in the activation of stem cells converting to progenitor cells in bald scalp.”
At this point, the researchers don’t know why there is a breakdown in this conversion. “However, the fact that there are normal numbers of stem cells in bald scalp gives us hope for reactivating those stem cells,” notes Cotsarelis.
In 2007, the Cotsarelis lab found that hair follicles in adult mice regenerate by re-awakening genes once active only in developing embryos. The team determined that wound healing in a mouse model created an “embryonic window” of opportunity to manipulate the number of new hair follicles that form. By activating dormant embryonic molecular pathways stem cells were coaxed into forming new hair follicles.
In the JCI study, the group also found a progenitor cell population in mice that is analogous to the human cells; these cells were able to make hair follicles and grow hair when injected into an immunodeficient mice.
The researchers say their next steps will be to study the stem and progenitor populations in other types of hair loss, including female pattern hair loss. The information may assist in developing cell-based treatments for male pattern balding by isolating stem cells and expanding them to add back to the scalp directly. They will also focus on identifying factors that could be used topically to convert stem cells to progenitor cells to generate normal large hairs.
First author Luis Garza, MD, PhD, a dermatologist and former postdoctoral fellow in the Cotsarelis lab, performed much of the work and is now an assistant professor of Dermatology at Johns Hopkins University.
The research was funded in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the Pennsylvania Department of Health; the Fannie Gray Hall Center for Human Appearance; and L’Oreal.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.